MET and non-small cell lung carcinoma: It is worth noting that both MET mutations and amplification are often detected in NSCLC and are associated with poor prognosis and resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) [19–21].